Brinsupri™
(brensocatib) tablets, 10 mg • 25 mg

GETTING PATIENTS STARTED

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.[1]

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Please see additional Important Safety Information throughout and full Prescribing Information.

BRINSUPRI may fit into a multimodal approach to managing bronchiectasis[1]

How to prescribe BRINSUPRI

- BRINSUPRI is available in dosage strengths of 10 mg or 25 mg to be taken orally once daily[1]
- **Fill out the BRINSUPRI Prescription and *inLighten*™ Enrollment Form** and submit via email or fax

—or—

- **E-prescribe via an EHR.** Consider using an NCPDP code for pharmacy identification

Remind patients

- BRINSUPRI can be taken once a day, any time of day, with or without food[1]
- Results can take time and may vary[1]
- Patients should speak with their doctor before making any changes in treatment
- If a patient misses a dose, they should take the next dose at their regular time the next day. They should not double the dose to make up for the missed dose[1]

BRINSUPRI is a limited-distribution product and can only be dispensed by[a]:

Amber Specialty Pharmacy
(888-370-1724) (NCPDP code: 2815338)

Maxor Specialty Pharmacy, A VytlOne Company
(800-658-6046) (NCPDP code: 4575518)

PANTHERx Rare Pharmacy
(855-726-8479) (NCPDP code: 6008002)

- Patients should expect a phone call from the specialty pharmacy

BRINSUPRI is indicated for patients diagnosed with bronchiectasis.[1] This may be based on clinical history and confirmed by chest computed tomography scan.

Example diagnosis codes[b]:

- ICD-10-CM J47.0: Bronchiectasis with acute lower respiratory infection
- ICD-10-CM J47.1: Bronchiectasis with (acute) exacerbation
- ICD-10-CM J47.9: Bronchiectasis, uncomplicated

[a]Separate distribution is available for 340B-eligible entities and patients insured by the US Department of Veterans Affairs.
[b]ICD-10-CM codes and descriptions are sourced from the Centers for Disease Control and Prevention and National Center for Health Statistics and are used in accordance with public domain guidelines. Information related to diagnostic codes is provided for reference only. Providers should fully evaluate patients and make an independent medical diagnosis and select diagnosis codes that are most appropriate for the specific patient's condition. This information does not guarantee that a patient is appropriate for, or will have insurance coverage for, BRINSUPRI.

EHR=electronic health record; NCPDP=National Council for Prescription Drug Programs.

Not actual size.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Gingival and Periodontal Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Please see additional Important Safety Information throughout and full Prescribing Information.

Brinsupri™
(brensocatib) tablets, 10 mg • 25 mg

Have questions about insurance coverage? Field Access Managers can assist

Field Access Managers[a] can provide the most recent publicly available payer-specific information regarding the approval process, prior authorization and reauthorization requirements, and the appeal process.

Some commercial insurance companies only cover BRINSUPRI for patients who have had ≥2 exacerbations in the past year.

To request a Field Access Manager, please visit BRINSUPRIhcp.com/request-a-rep

inLighten™ Patient Support

Once enrolled in *inLighten*, patients can get one-on-one support with:

- Navigating the prescription approval process
- Understanding copay savings eligibility
- Scheduling and tracking shipments
- Answering questions throughout their treatment journey

The BRINSUPRI Copay Savings Program

- Patients with commercial or private insurance may be able to get their prescription for as little as $0 with the BRINSUPRI Copay Savings Program
- Eligibility can be determined by calling *inLighten* at **833-LIGHT-00 (833-544-4800)** Monday–Friday, from 8 AM to 8 PM ET
- Not valid for patients insured by Medicaid, Medicare, Veterans Affairs, Department of Defense, TRICARE or similar federal or state programs, including any state pharmaceutical assistance program

[a]The role of the Field Access Manager is informational only. They cannot fill out or submit any paperwork on behalf of the prescriber or facilitate the prior authorization process in any way.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Live Attenuated Vaccines

It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

Please see additional Important Safety Information throughout and full Prescribing Information.

Brinsupri™
(brensocatib) tablets, 10 mg • 25 mg

Ready to prescribe BRINSUPRI?

You can also help your patients enroll in the *inLighten Patient Support* program

To get your patients started with BRINSUPRI, download the BRINSUPRI Prescription and *inLighten* Enrollment Form

Submit the form via email or fax. Patients can also sign up for *inLighten* at **brinsupri.inlightensupport.com**


Patient Enrollment Form

Brinsupri (brensocatib) 10mg, 25mg

inLighten

PATIENT INFORMATION

Prescription Insurance Information

Please see Indication and Important Safety Information for BRINSUPRI on page 4 and accompanying full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS

The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information.

Reference: 1. BRINSUPRI [package insert]. Bridgewater, NJ: Insmed Incorporated; 2025.

insmed

Brinsupri™
(brensocatib) tablets, 10 mg • 25 mg